Theralase's ruvidar shown effective for herpes simplex

Executive Summary

• Theralase Technologies Inc. published peer-reviewed preclinical data in MDPI -- Viruses demonstrating that its lead anti-viral candidate, ruvidar, is superior to the current gold-standard treatment, acyclovir, and metformin, in destroying Herpes Simplex Virus Type 1 (HSV-1).
• The research highlights ruvidar's ability to inhibit viral replication post-infection without light activation, protect uninfected cells from contracting HSV-1, and effectively treat acyclovir-resistant HSV-1 mutants.
• Based on these results, Theralase has commenced formulation of ruvidar into a topical form, plans to initiate GLP toxicology analysis, and intends to begin a Phase 1/2 adaptive clinical study in 2026 to evaluate safety and efficacy for accelerating cold sore healing.

Key Details

• Publication Details: Data published in MDPI -- Viruses under the title "Ruvidar -- An Effective Anti-Herpes Simplex Virus Agent."
• Comparative Efficacy: Ruvidar demonstrated superior effectiveness compared to acyclovir and metformin, even without light activation.
• Post-Infection Activity: Unlike acyclovir and metformin, which had little to no effect once infection was established, ruvidar showed a dramatic inhibitory effect on HSV-1 in cells harboring active infection.
• Prophylactic Protection: Ruvidar prevented non-infected cells from contracting HSV-1, minimizing disease spread to adjacent cells and potentially reducing patient duration of the disease.
• Drug-Resistant Strains: Ruvidar was effective against acyclovir-resistant HSV-1 mutants, offering a potential solution for patients with resistant infections.
• Combination Therapy: The combination of ruvidar with acyclovir proved more effective than either agent used alone.
• Mechanism of Action: Ruvidar is effective on a molar basis, reducing virus yields from new infections more effectively than acyclovir, and remains effective in deep tissue applications where light cannot penetrate.
• Next Steps:
  • Commenced formulation of ruvidar into a topical form.
  • Plans to commence GLP toxicology analysis.
  • Plans to commence a Phase 1/2 adaptive clinical study in 2026 to demonstrate safety and efficacy for accelerated healing of cold sore lesions in humans.
• Market Context: The global HSV treatment market was estimated at $2.8 billion (U.S.) in 2024 and is projected to reach $4.7 billion by 2033.

Notable Quotes

• Kevin M. Coombs, PhD (Professor, University of Manitoba): "Head-to-head comparisons of ruvidar with acyclovir demonstrate that ruvidar is much more effective in attenuating HSV-1 in a number of ways... unlike acyclovir, which is ineffective against already-infected cells, ruvidar was highly effective against HSV-1 in cells that already harbour infection... ruvidar remained highly effective against every acyclovir-resistant HSV mutant that we tested, providing hope for patients for which acyclovir has become ineffective."
• Arkady Mandel, MD, PhD, DSc (Chief Scientific Officer, Theralase): "Theralase's advanced, anti-viral technology has demonstrated very high efficacy preclinically in numerous pathogenic human viruses... Ruvidar has the added benefit of being able to be effective, with or without light activation, thus allowing it to be effective in deep tissue clinical applications... We believe that the ruvidar-based platform technology offers significant potential to fight a broad spectrum of viruses..."
• Roger DuMoulin-White, BSc, PEng, ProDir (President and CEO, Theralase): "The latest peer-reviewed preclinical data... demonstrated the superiority of ruvidar in the effective destruction of HSV-1 lesions versus acyclovir and the ability of ruvidar to provide efficacy in acyclovir-resistant HSV-1 cells. Based on the success of this latest preclinical research, Theralase has commenced formulation of ruvidar into topical form... and plans to commence a phase 1/2 adaptive clinical study... in 2026."